Everyday Health on MSN
What’s the difference between chronic inflammatory demyelinating polyneuropathy and Guillain-Barré syndrome?
Learn the key differences between CIDP and GBS, including causes, onset, and treatments, to ensure you get the correct ...
(BPT) – “At first I was kind of like, what is that? What is CIDP? I’ve never heard of that. But then, the relief set in more than confusion … because at least there was a name to what I had.” ...
Please provide your email address to receive an email when new articles are posted on . Reasons for misdiagnosis or delayed diagnosis for CIDP are complex and include multiple factors. The FDA ...
Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that ...
Victoria Johnston, 35, from Milton Keynes says her life was turned upside down after she collapsed at work and was unable to ...
Everyday Health on MSN
Chronic inflammatory demyelinating polyneuropathy (CIDP) treatments
Explore comprehensive treatments for CIDP, including corticosteroids, plasma exchange, immunoglobulin therapy, and others.
Investigational therapies may soon change the treatment landscape for chronic inflammatory demyelinating polyneuropathy (CIDP). "Despite the fact that we have some good standard-of-care therapies -- ...
CIDP treatment focuses on reducing and slowing the immune processes damaging your peripheral nervous system. It includes corticosteroids, intravenous immunoglobulin, and plasma exchange, but new ...
Findings show that convenience of treatment and flexibility of administration, such as at-home treatment options, are of high importance to patients KING OF PRUSSIA, Pa., Jan. 16, 2024 /PRNewswire/ -- ...
Victoria Johnston, 35, was fit and healthy when she collapsed at work in 2022 and was unable to feel her legs beneath her ...
NVG-2089 is a recombinant Fc fusion protein designed to replicate key immunomodulatory functions of IVIg with greater consistency, scalability, and patient convenience Phase 1 data show NVG-2089 was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results